Organigram's Q4 2025 results showed strong revenue growth driven by international sales and acquisitions. However, the company reported a larger net loss due to non-cash fair value adjustments.

Organigram achieved its second consecutive quarter of record revenue in Q3 2025, led by the Motif acquisition, robust international sales, and U.S. market entry. Despite a net loss, the company saw strong adjusted EBITDA and positive free cash flow.